Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Higher 25(OH)D levels (p < 0.001) are found in patients with low BMD.

Source: Risk factors for low BMD in rheumatic and immunological diseases. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

In total, 1845 patients were approached in this manner.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Impact of immunosuppressive therapy and clinical risk factors on the prevalence of low bone mineral density in rheumatic diseases

Study design awaiting verification · Frontiers in Medicine · 2026

Original publication title

Impact of immunosuppressive therapy and clinical risk factors on the prevalence of low bone mineral density in rheumatic diseases

Jan-Michael Brandt; Margret Patecki; Torsten Witte; Kai Schmidt-Ott; Vega Gödecke; Stefanie Hillmer

© 2026 Brandt, Patecki, Witte, Schmidt-Ott, Gödecke and Hillmer.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Patients with rheumatic diseases exhibit a substantial and clinically relevant prevalence of low BMD. Our findings highlight an association between alcohol consumption and low BMD. The association of specific csDMARDs likely reflects higher cumulative disease severity, necessitating intensified bone density monitoring in these treatment groups.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Osteoporosis is a severe comorbidity in inflammatory rheumatic diseases, impacting patient quality of life and healthcare costs. While general risk factors are known, the specific influence of various immunosuppressive therapies across different disease entities requires further characterization. This study aimed to determine the prevalence of low bone mineral density (BMD), identify clinical risk factors, and assess medication-associated factors in a large university cohort.

Source: Background

Abstract: What methods does the paper describe?

A cross-sectional study of 704 adult patients receiving care at the specialized Rheumatology Outpatient Clinic of the Hannover Medical School was conducted. Data on lifestyle, medical history, and medication were collected via specialized questionnaires and electronic records. Low BMD was defined as a T-score ≤ −1.0. Statistical analyses included Pearson's chi-squared, Welch t-tests, and Wilcoxon rank-sum tests.

Source: Methods

Abstract: Results

The prevalence of low BMD was 56%. Rheumatoid arthritis (RA) (65.8%) and systemic lupus erythematosus (SLE) (60.2%) showed the highest rates. Beyond age, female gender, and low BMI, alcohol consumption was significantly associated with low BMD across several diseases (RA: p = 0.009; SLE: p < 0.001; Sjögren's syndrome: p = 0.014). Regarding therapy, use of conventional synthetic DMARDs (csDMARDs) was associated with higher low BMD prevalence in RA (p = 0.005), specifically hydroxychloroquine (p = 0.016). Mycophenolate mofetil in SLE (p = 0.037) and hydroxychloroquine in other connective tissue diseases (p = 0.027) were also significant factors.

Source: Results

Abstract: Conclusion

Patients with rheumatic diseases exhibit a substantial and clinically relevant prevalence of low BMD. Our findings highlight an association between alcohol consumption and low BMD. The association of specific csDMARDs likely reflects higher cumulative disease severity, necessitating intensified bone density monitoring in these treatment groups.

Source: Conclusion
Authors’ abstract

Background

Osteoporosis is a severe comorbidity in inflammatory rheumatic diseases, impacting patient quality of life and healthcare costs. While general risk factors are known, the specific influence of various immunosuppressive therapies across different disease entities requires further characterization. This study aimed to determine the prevalence of low bone mineral density (BMD), identify clinical risk factors, and assess medication-associated factors in a large university cohort.

Methods

A cross-sectional study of 704 adult patients receiving care at the specialized Rheumatology Outpatient Clinic of the Hannover Medical School was conducted. Data on lifestyle, medical history, and medication were collected via specialized questionnaires and electronic records. Low BMD was defined as a T-score ≤ −1.0. Statistical analyses included Pearson's chi-squared, Welch t-tests, and Wilcoxon rank-sum tests.

Results

The prevalence of low BMD was 56%. Rheumatoid arthritis (RA) (65.8%) and systemic lupus erythematosus (SLE) (60.2%) showed the highest rates. Beyond age, female gender, and low BMI, alcohol consumption was significantly associated with low BMD across several diseases (RA: p = 0.009; SLE: p < 0.001; Sjögren's syndrome: p = 0.014). Regarding therapy, use of conventional synthetic DMARDs (csDMARDs) was associated with higher low BMD prevalence in RA (p = 0.005), specifically hydroxychloroquine (p = 0.016). Mycophenolate mofetil in SLE (p = 0.037) and hydroxychloroquine in other connective tissue diseases (p = 0.027) were also significant factors.

Conclusion

Patients with rheumatic diseases exhibit a substantial and clinically relevant prevalence of low BMD. Our findings highlight an association between alcohol consumption and low BMD. The association of specific csDMARDs likely reflects higher cumulative disease severity, necessitating intensified bone density monitoring in these treatment groups.

Publication and source details

Original title: Impact of immunosuppressive therapy and clinical risk factors on the prevalence of low bone mineral density in rheumatic diseases

Jan-Michael Brandt; Margret Patecki; Torsten Witte; Kai Schmidt-Ott; Vega Gödecke; Stefanie Hillmer

Frontiers in Medicine · 2026

* Correspondence: Margret Patecki patecki.margret@mh-hannover.de
†

These authors have contributed equally to this work and share first authorship

‡

These authors have contributed equally to this work and share senior authorship

© 2026 Brandt, Patecki, Witte, Schmidt-Ott, Gödecke and Hillmer.2026Brandt, Patecki, Witte, Schmidt-Ott, Gödecke and Hillmerhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was received for this work and/or its publication. The publication costs for this article were funded by the German Research Foundation (DFG) Publication Fund 2026 at Hannover Medical School.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:40:56.922627+00:00

DOI: 10.3389/fmed.2026.1897856 · PMC13616625